Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Takeda Ups Full-Year Profit Guidance after EU Clears Obligation to Divest SHP647
Takeda Pharmaceutical’s April-June operating profit spiked 3.7-fold compared to a year earlier on a one-time gain after European regulators released the company from its commitment to divest ex-Shire’s pipeline compound SHP647, according to its earnings released on July 31. In…
To read the full story
Related Article
- Takeda’s Q1 Sales Rise on Diabetes Divestiture; Plant Re-Inspection Results Expected Late October
August 2, 2021
- Takeda’s FY2020 Profits Jump on Non-Core Divestitures, Post-Shire Cost Synergies
May 12, 2021
- Takeda’s 9-Month Sales Skid 3.6% on Dips in Rare Diseases, Neuroscience
February 5, 2021
- Takeda’s Half-Year Operating Profit Nearly Doubles on Drop in Costs, Shire Synergies
October 30, 2020
- Takeda to Book One-Time Profit Gains after SHP647 Divestment Obligation Cleared
June 23, 2020
- Takeda’s FY2019 Revenue Up 57% on Shire Buy, Underlying Growth at 1.6%
May 14, 2020
BUSINESS
- CSL Behring Japan Names Edward Wright as New Chief
October 2, 2026
- Takeda Welcomes 39 Prospective 2027 Hires in Japan
October 2, 2026
- Nippon Shinyaku Reports 5-Year Efficacy Data for DMD Hopeful
October 2, 2026
- Taiho’s ASTX030 Hits PIII Goal, US Filing Planned
October 2, 2026
- Ono Moves US Venture Capital Arm to Cambridge
October 2, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…